DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates

AudioMedica News
AudioMedica News
DUET 1 and 2 Trials: TMC 125 has Superior Virologic and Immunologic Response Rates
Loading
/
Pedro Cahn
Pedro Cahn

REFERENCE: Abstract H-717, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
PEDRO CAHN, Juan A. Fernández Hospital, Buenos Aires
Etravirine provides a chance to rescue patients who are failing non-nucleoside regimens according to 24-week pooled results of the DUET-1 and -2 studies. Nicola Solomon discussed these major trials with Pedro Cahn, of Juan A. Fernández Hospital in Buenos Aires.

[audio:https://www.audiomedica.com/podcasting/general_medicine/070919PedroCahn.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality